Prescribing
US$ 22.17
glp 1 ra Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment Emerging Frontiers in GLP-1 Therapeutics:
Description
Systolic blood pressure reduction with Tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
2012 Jan;9(1):79
If we could support the bodys own GLP-1 production while on the GLP-1 drugs, reduce the factors that disrupt the bodys self-regulatory mechanisms and get our internal processes back on track we should be able to lose weight on the drugs and then keep it off
But its not clear how well it works in humans
